SeaStar Medical ICU 深 滬
等待開盤 09-25 09:30:00 美东时间
3.485
-0.045
-1.27%
華盛通- 最 高3.49
- 今 開3.49
- 成交量 1.02万股
- 最 低 3.2206
- 昨 收 3.53
- 總市值 1535.78万
- 52周最高 7.35
- 市盈率 靜 --
- 換手率 0.23%
- 52周最低 2.07
- 委 比 1.48%
- 總股本 440.68万
- 歷史最高 3050.00
- 量 比 0.30
- 振 幅 7.63%
- 歷史最低 2.20
- 每 手 1
- 風險率 1.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SeaStar Medical Launches Executive Retention Bonus Program
SeaStar Medical Holding ( ($ICU) ) just unveiled an update. On June 25, 2026, S...
07-02 04:36
SeaStar Medical's Selective Cytopheretic Device Receives Dedicated International Classification of Diseases Codes From U.S. CMS, Facilitating Future Billing Procedures
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Selective Cytopheretic Device (SCD) therapy has received dedicated ICD-1...
06-23 20:29
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Maxim Group Maintains Buy on SeaStar Medical Holding, Raises Price Target to $8
Maxim Group analyst Anthony Vendetti maintains SeaStar Medical Holding (NASDAQ:ICU) with a Buy and raises the price target from $6 to $8.
05-15 04:45
Full Transcript: SeaStar Medical Holding Q1 2026 Earnings Call
On Wednesday, SeaStar Medical Holding (NASDAQ:ICU) discussed first-quarter fina...
05-14 05:20
SeaStar Medical Holding Q1 EPS $(0.90) Misses $(0.82) Estimate, Sales $495.000K Beat $437.500K Estimate
SeaStar Medical Holding (NASDAQ:ICU) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.82) by 9.76 percent. This is a 79.45 percent increase over losses of $(4.38) per
05-14 04:09
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
SeaStar Medical announced new data from the SAVE Registry, showing no device-related adverse events and strong survival rates in pediatric patients with AKI and sepsis treated with its SCD therapy. In vitro research highlights the device's immunomodulatory effects, shifting monocytes to an anti-inflammatory state. The company also hosted a symposium on pediatric AKI innovation, underscoring its leadership in this field.
03-30 12:20
SeaStar Medical Holding Q4 EPS $(0.80) Beats $(1.01) Estimate, Sales $420.000K Beat $372.500K Estimate
SeaStar Medical Holding (NASDAQ:ICU) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.01) by 21.18 percent. This is a 91.11 percent increase over losses of $(9.00) per share
03-26 04:07
Earnings Scheduled For March 25, 2026
Companies Reporting Before The Bell • Chewy (NYSE:CHWY) is expected to report q...
03-25 19:11
